pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
EMERGENT · news · pharmadog
← back to EMERGENT
News mentioning EMERGENT
50
stories
8h
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
biospace
1d
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
biospace
1d
Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles
fiercebiotech
8d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
11d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
14d
Rapport’s epilepsy drug finds surprising success in bipolar trial
biopharma dive
14d
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial
biospace
15d
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep
biospace
15d
Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
biospace
15d
Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drug
fiercebiotech
15d
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
15d
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
fiercebiotech
19d
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
biospace
20d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
21d
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 17, 26
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
biospace
Sep 17, 26
Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
fiercebiotech
Sep 16, 26
Sling catches $123M series C for thyroid eye disease pill
biospace
Sep 14, 26
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
Sep 14, 26
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
biospace
Sep 9, 26
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
fiercebiotech
Sep 8, 26
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
biospace
Sep 8, 26
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Aug 31, 26
Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
biospace
Aug 27, 26
Generate Bio drops as data accidentally leaked ahead of European conference
biospace
Aug 17, 26
Intraosseous Needle Set Recall: Becton Dickinson Removes Certain Intraosseous Vascular Access System Needle Sets
fda medwatch
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
← prev
page 1 of 2
next →
